IQV vs. RVMD: IQVIA vs. Revolution Medicines Stock Comparison

November 11, 2026

How do IQVIA (IQV) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

IQVIA (IQV) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Company profile comparison for IQVIA (IQV) and Revolution Medicines (RVMD)
Profile Item	IQV	RVMD
Name	IQVIA Holdings Inc.	Revolution Medicines, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	44.80 billion USD	41.59 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 9, 2013	February 13, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

IQV

RVMD

GSPC

IQVIA (IQV) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for IQVIA (IQV) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for IQVIA (IQV) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Total Return (1Y)	32.11%	224.80%
Total Return (3Y, Annualized)	13.15%	114.71%
Total Return (5Y, Annualized)	2.00%	43.47%

Risk Profile

Drawdown History

IQV

RVMD

GSPC

IQVIA (IQV) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for IQVIA (IQV) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Volatility (1Y, Annualized)	40.77%	68.29%
Beta (5Y)	1.14	1.42
Max Drawdown (5Y)	-51.52%	-55.71%
Avg. Volume (3M)	1.40M	2.06M

Risk-Adjusted Performance

Risk-Return Positioning

IQV and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Sharpe Ratio (1Y)	0.68	3.23
Sortino Ratio (1Y)	1.03	6.92

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IQVIA (IQV) reports 21.39%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max: 109.18%
IQV: 21.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
RVMD: -93.56%
Min: -167.77%

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

IQVIA (IQV) at 8.05% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max: 18.05%
IQV: 8.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
RVMD: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile IQVIA (IQV) reports 13.73%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max: 83.12%
Q3: 14.77%
IQV: 13.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
RVMD: -188.88%
Min: -207.40%

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
ROE (TTM)	21.39%	-93.56%
ROA (TTM)	5.08%	-32.13%
Net Margin (TTM)	8.05%	0.00%
Operating Margin (TTM)	13.73%	-188.88%
Gross Margin (TTM)	33.07%	0.00%

Growth

Revenue Growth

Only one side can be read here: IQVIA (IQV) reports revenue growth of 5.87%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Revenue Growth (YoY)	5.87%	--
Revenue Growth (3Y CAGR)	4.21%	--
EPS Growth (YoY)	4.67%	--
EPS Growth (3Y CAGR)	11.08%	--

Financial Strength

Current Ratio (MRQ)

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IQV.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
IQV: 0.83
Min: 0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max: 25.13
Q3: 12.13
RVMD: 8.36
Median: 5.52
Q1: 2.47
Min: 0.10

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revolution Medicines (RVMD) at 0.50 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV: 2.40
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max: 1.42
Q3: 0.65
RVMD: 0.50
Median: 0.15
Q1: 0.02
Min: 0.00

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Current Ratio (MRQ)	0.83	8.36
Debt / Equity (MRQ)	2.40	0.50
Net Debt / EBITDA	4.46	--

Dividends

Dividend Yield (TTM)

Neither IQVIA (IQV) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither IQVIA (IQV) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: IQVIA (IQV) trades at 33.07 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max: 85.34
Q3: 43.46
IQV: 33.07
Median: 26.69
Q1: 13.30
Min: 0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RVMD: --

IQVIA (IQV) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; IQV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Revolution Medicines (RVMD) at 210.51 prices above its industry range — a wide gap in sales valuation between them.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
IQV: 2.59
Min: 0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD: 210.51
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: IQVIA (IQV) at 6.73 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max: 13.53
IQV: 6.73
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD: 17.31
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

IQVIA (IQV) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for IQVIA (IQV) and Revolution Medicines (RVMD)
Metric	IQV	RVMD
P/E Ratio (TTM)	33.07	--
P/S Ratio (TTM)	2.59	210.51
P/B Ratio (MRQ)	6.73	17.31
Free Cash Flow Yield (TTM)	4.72%	-2.13%